Emergent BioSolutions has entered into a definitive agreement to acquire PaxVax, which is majority owned by an affiliate of Cerberus Capital Management, L.P. The acquisition, subject to customary closing conditions, is expected to close in 4Q18. The agreement will create a focus on infectious diseases through the development and commercialization of novel specialty vaccines, while ensuring uninterrupted supply of Vaxchora and Vivotif. PaxVax has capabilities across R&D, manufacturing a...